The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise

ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise

May 1, 2013 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Explore This Issue
May 2013
Also By This Author
  • Pain Management for the Person with RA: An Occupational Therapist’s Perspective
New Kinase Inhibitors Show Promise


SNOWMASS, COLO.—“We are currently in the era of biologics,” said Gary S. Firestein, MD, dean and associate vice chancellor of translational medicine at the University of California San Diego School of Medicine in La Jolla, Calif., at a session titled, “Primer on Signaling,” here at the ACR Winter Rheumatology Symposium, held January 26–February 1, 2013. “The next wave of therapeutics will most likely focus on small molecules,” including kinase inhibitors, which affect signal transduction, he says. There are many pros and cons with these molecules, and the research is ongoing. As with many therapeutics used for rheumatic disease, the task for clinicians is to weigh the potential benefit against potential toxicities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Signal Transduction

Signal transduction is a communication system that relays information from the environment to the interior of a cell so it can appropriately respond to stresses, Dr. Firestein said. Kinases are enzymes that participate in signaling cascades that affect cell functions such as mRNA transcription and stability and protein production and stability.

The therapeutic application of kinase inhibitors is under investigation in diverse signaling pathways: examples include mitogen-activated protein kinases (MAPK), Janus kinase (JAK), and spleen tyrosine kinase (Syk). In general, these pathways are systems that sense the environment through a cytokine receptor or immunoreceptor, and via adaptor molecules, initiate a series of events that alter cell function, Dr. Firestein said. Kinases amplify signals by increasing function in an enzymatic cascade.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Big Interest in Small Molecules

Altered cellular signaling is associated with chronic inflammatory disease, and understanding these intracellular pathways might lead to new approaches for treatment, including the use of orally bioavailable small molecules that regulate cytokine function and production.1 Small molecule tyrosine kinase inhibitors such as imatinib and erlotinib are of particular therapeutic interest in cancer because they have broad specificity that probably contributes to efficacy, Dr. Firestein noted, adding that they are also oral and less expensive to produce.

One drawback with small molecules is the potential for toxicity and “off-target” effects compared with antibodies. They are chemically derived, and can effectively block a targeted enzyme, but they also may affect other cellular proteins and cause unexpected side effects. This prompts the question about the importance of selectivity and the best location in the pathway to intercede, Dr. Firestein said. “Do we want to go high in the signaling cascade so there are more pathways affected, but also more toxicity, or farther down where it is more tightly targeted but less likely to work?” he posed.

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates, Meeting Reports Tagged With: AC&R, ACR Winter Rheumatology Symposium, kinase inhibitor, ResearchIssue: May 2013

You Might Also Like:
  • As Role of Kinase Inhibitors in Rheumatic Disease Treatment Expands, Experts Review Therapy’s Failures, Successes
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
  • Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.